EX-23.1 3 a2238283zex-23_1.htm EX-23.1
QuickLinks -- Click here to rapidly navigate through this document

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)
  Registration Statement (Form S-8 No. 333-191161) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan
(2)
  Registration Statement (Form S-8 No. 333-194228) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan
(3)
  Registration Statement (Form S-8 No. 333-204210) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan
(4)
  Registration Statement (Form S-8 No. 333-210694) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan
(5)
  Registration Statement (Form S-8 No. 333-215575) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan
(6)
  Registration Statement (Form S-8 No. 333-222400) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan
(7)
  Registration Statement (Form S-8 No. 333-226199) pertaining to the Onconova Therapeutics, Inc. 2018 Omnibus Incentive Compensation Plan
(8)
  Registration Statement (Form S-3 No. 333-221684) of Onconova Therapeutics, Inc.
(9)
  Registration Statement (Form S-1 No. 333-207533) of Onconova Therapeutics, Inc.
(10)
  Registration Statement (Form S-1 No. 333-211769) of Onconova Therapeutics, Inc.
(11)
  Registration Statement (Form S-1 No. 333-222374) of Onconova Therapeutics, Inc.
(12)
  Registration Statement (Form S-1 No. 333-224315) of Onconova Therapeutics, Inc.

of our report dated April 1, 2019, with respect to the consolidated financial statements of Onconova Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2018.

|  | /s/ Ernst & Young LLP
Philadelphia, Pennsylvania April 1, 2019 |  |

QuickLinks

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm